ALPCO
Salem, New Hampshire, 03079, United States
NCT Number: NCT07830550
This prospective, single-center study will collect blood from approximately 50 adult volunteers aged 22 years or older. Participants will provide informed consent, complete an eligibility review, and undergo one blood draw of approximately 20-50 mL.
The blood will be processed into serum and labeled with a study identification number. The serum may be used to prepare laboratory samples with defined antibody levels to support the development and performance evaluation of the ALPCO Syphilis-T and Syphilis-NT assays. All testing is for research purposes only. Individual test results will not be provided to participants or used for diagnosis or treatment.
Interested in participating?
Request Info22 year and older
All sexes
Observational
Salem, New Hampshire, 03079, United States
Syphilis is a sexually transmitted infection caused by the bacterium Treponema pallidum. Laboratory diagnosis commonly includes treponemal tests, which detect antibodies specific to T. pallidum, and non-treponemal tests, which detect antibodies associated with cellular damage and may help assess disease activity.
Serum collected under this study will serve as a human serum matrix for preparing contrived specimens. These specimens may be created by adding characterized reactive serum or other appropriately characterized materials to produce predefined levels of treponemal or non-treponemal reactivity. Before use, the serum may be evaluated using appropriate reference or comparator methods to confirm its suitability.
The resulting specimens will support analytical and, when scientifically and regulatorily appropriate, clinical performance evaluations of the ALPCO Syphilis-T and Syphilis-NT assays. The specific preparation procedures, target reactivity levels, testing methods, and acceptance criteria will be defined in the applicable performance-study protocols.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Approximately 20-50 mL of whole blood will be collected during one study visit by qualified personnel using standard venipuncture procedures. The blood will be processed to obtain serum for research use in developing and evaluating the ALPCO Syphilis-T and Syphilis-NT assays.
Detection of antibodies to lipoidal antigens in human serum and plasma
Time frame: Day 1, following the single study visit and serum processing
The number of enrolled participants from whom approximately 20-50 mL of whole blood is successfully collected and processed into serum suitable for research use in the development and performance evaluation of the ALPCO Syphilis-T and Syphilis-NT assays.
American Laboratory Products Company
Industry
ALPCO Syphilis-T (Treponema Pallidum) CLIA Kit and ALPCO Syphilis-NT (Non-Treponemal Lipoidal Antigen) CLIA Kit Blood Donation Protocol
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00071045
Healthy Volunteers, Hematologic Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT07662954
Behavior, Echocardiography
Karaman, Turkey (Türkiye)
View Trial DetailsNCT07198711
Healthy Volunteers
Stanford, California, United States
View Trial DetailsNCT07634133
Healthy Volunteers
Katowice, Poland
View Trial Details